LeonaBio

Developing novel therapeutics for diseases with high unmet medical needs

[LeonaBio @leonabioinc]

LeonaBio lighting up Times Square as our new name appears on the Nasdaq Tower.
Our stock now trades under $LONA.
Derived from “Leona,” meaning lioness, LeonaBio represents strength, resilience, and our commitment to patients facing serious diseases.
#LeonaBio #LONA #Nasdaq

[LeonaBio @leonabioinc]

Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Our Nasdaq ticker will change to LONA, effective January 12, 2026.
https://t.co/q7p9ZS5WUj

[LeonaBio @leonabioinc]

Athira Pharma will focus on advancing the clinical development program for ATH-1105 as a potential treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (#ALS) and Alzheimer’s Disease (#AD).

Read the full announcement: https://t.co/J3jFwvxP5z

[LeonaBio @leonabioinc]

Today we announced the topline results from our Phase 2/3 LIFT-AD Study of #fosgonimeton for mild-to-moderate Alzheimer’s disease.

Read the full release and join our live webcast today at 4:30 pm ET, where management will discuss the study results: https://t.co/qextmePGSP

[LeonaBio @leonabioinc]

#ICYMI – Take a deep dive into our latest corporate and pipeline updates, company highlights, news, and events compiled for easy access.

See it here: https://t.co/83LCAJNSJr

[LeonaBio @leonabioinc]

Our Phase 2/3 LIFT-AD Study is evaluating the safety and efficacy of #fosgonimeton for the treatment of mild-to-moderate #AlzheimersDisease.

Hear more on our company progress from CEO Mark Litton, Ph.D. as we approach our topline data readout of the clinical trial.

[LeonaBio @leonabioinc]

Fosgonimeton has the potential to address the mild-to-moderate stage of #AD by providing neuroprotection and neuronal restoration. Stay tuned as we report topline data from our Phase 2/3 LIFT-AD clinical trial in Alzheimer's.

Learn more: https://t.co/NPTK7gnQeG #ENDALZ

[LeonaBio @leonabioinc]

The #Alzheimers space is poised for significant developments in the second half of 2024. In her recent @biospace article, @hmac8 summarizes key data readouts, including our LIFT-AD Phase 2/3 topline results of #fosgonimeton as a potential #AD treatment. https://t.co/RxlwAsva7j

[LeonaBio @leonabioinc]

That’s a wrap on #AAIC24! Thank you for joining our discussion of #fosgonimeton’s neuroprotective preclinical activity in #AD models.

See you next year!

[LeonaBio @leonabioinc]

Today we reported our second quarter 2024 financial results and provided recent pipeline and business updates.

See full details here: https://t.co/anfvPopyMv $ATHA

[LeonaBio @leonabioinc]

We participated in the 2024 @alzassociation International Conference (AAIC), where our team presented preclinical data demonstrating new insights into the mechanism by which #fosgonimeton protects neurons from Alzheimer’s disease-related pathology.
https://t.co/AkkFTUHVKq #AAIC24

[LeonaBio @leonabioinc]

Last week, the #AthiraTeam gathered for an ice cream social hour at our Seattle office to catch up and decompress over tasty treats. Big thank you to our admin team for hosting the event, we’re grateful for the opportunity to bring the team together!

[LeonaBio @leonabioinc]

Disease-modifying treatments are pivotal to effectively tackle #Alzheimers and potentially reverse neurodegeneration progression. Hear from Dr. Porsteinsson on the need for new treatments to reduce patient burden below.

Listen to the full webinar: https://t.co/kqWYcdTt6o

[LeonaBio @leonabioinc]

What’s at stake for us? Developing therapies to counteract progression of neurodegenerative disease.

President & CEO Mark Litton, Ph.D. joined Life Science Leader’s @WayneKoberstein to highlight our approach, progress, and future.

https://t.co/HAL1VLzhSo #CompaniesToWatch

[LeonaBio @leonabioinc]

The last patient has completed dosing in our Phase 2/3 LIFT-AD clinical trial evaluating #fosgonimeton in mild-to-moderate #Alzheimers disease, with topline results anticipated by end of Q3 2024.

Read the full announcement: https://t.co/KeiaHXy7AD $ATHA

[LeonaBio @leonabioinc]

As scientific pioneers, we’re taking a new approach to tackling Alzheimer's disease.

Listen to CEO Mark Litton, Ph.D. explain fosgonimeton’s mechanism of action in a recent conversation with Precision AQ:

[LeonaBio @leonabioinc]

Pride creates a space of reflection, solidarity, empowerment and joy. As we wrap up #Pride month, join us in recognizing the impact of pride in fostering an inclusive and supportive environment promoting diversity, equity, and support, which we aim to nurture at Athira.

[LeonaBio @leonabioinc]

This Alzheimer’s and Brain Awareness Month, we’re honored join the conversations bringing awareness, understanding and support for the #Alzheimers community. Hear more from our CMO Javier San Martin, M.D. on the unmet need for new, effective therapies for patients. #ENDALZ

[LeonaBio @leonabioinc]

Thank you all who joined our webinar on the LIFT-AD clinical trial and endpoints this past week!

Missed the session and interested in learning more about the trial and need for effective #Alzheimers treatments? Check out the webinar recording here: https://t.co/kqWYcdTt6o $ATHA

[LeonaBio @leonabioinc]

Today we join @ALSMNDAlliance in celebrating a global day of recognition and awareness for ALS/MND disease. At Athira, we're advancing our investigational ALS treatment, ATH-1105, for the potential benefit of the ALS community.

https://t.co/HwyB26wwOA #ALSMNDWithoutBorders